ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinsons Disease
December 05, 2025 08:00 ET Â | Source: Amneal Pharmaceuticals LLC Interim data…
Cango Inc. Reports Third Quarter 2025 Unaudited Financial Results
DALLAS, Dec. 2, 2025 /PRNewswire/ -- On December 1, Cango Inc. (NYSE:…
Kia Announces November 2025 Global Sales Results
November 2025 global sales of 262,065 units, down 0.8% Y/yIn Korea, Kia…
BIGG Digital Assets Inc. Reports Financial Results for Q3 2025
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- BIGG Digital Assets…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
November 26, 2025 19:00 ET Â | Source: HUTCHMED (China) Limited HONG KONG…